Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Relapsed and Refractory Multiple Myeloma Treatment Market: By Treatment Type, By Drug Class, By Route of Administration, By Distribution Channel, and Geography
Relapsed and Refractory Multiple Myeloma Treatment Market size was valued at US$ 19.8 billion in 2023 and is poised to grow at a CAGR of 4.4% from 2024-2030. The increase in the prevalence of multiple myeloma. According to World Cancer Research Fund International 2012, approximately 114,000 multiple myeloma cases are observed around the world. According to Novartis data 2015, approximately 75,000 people are living with relapsed and refractory multiple myeloma around the globe.
Moreover, a strong product pipeline for relapsed and refractory multiple myeloma treatment is expected to boost the market. For instance, in April 2017, Genmab A/S announced that Janssen Research and Development LLC collaborated with the European Myeloma Network (EMN) to start a phase III study of daratumumab in combination with dexamethasone and pomalidomide in relapsed and refractory multiple myeloma. In addition, FDA approval for various drugs might upsurge the revenue of the market.
For instance, in January 2016, Amgen received FDA approval for a supplemental New Drug Application (sNDA) of Kyprolis (carfilzomib) injection in combination with lenalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma. Relapsed multiple myeloma occurs when the multiple myeloma disease or its signs and symptoms return after a period of improvement. Relapsed and Refractory Multiple Myeloma Treatment Market occurs when the disease is unresponsive to a primary therapy or it becomes unresponsive over time. Multiple myeloma or plasma cell myeloma, is a cancer of plasma cells, a type of WBC normally responsible for the production of antibodies. At the initial stage, there are no symptoms noticed with multiple myeloma,
However, in the advanced stage bleeding, bone pain, anemia, and frequent infections may occur. Risk factors for multiple myeloma are high consumption of alcohol and obesity. It may be caused by abnormal production of antibodies may cause renal problems and an increase in the thickness of blood. The disease can be considered treatable, but incurable. It can be treated with radiotherapy, chemotherapy, and stem cell transplantation among others.
Study Period
2024-2030Base Year
2023CAGR
4.4%Largest Market
North AmericaFastest Growing Market
North-America
Increase in the prevalence of relapsed and refractory multiple myeloma, rise in R&D for the innovation of newer drugs, funding for the R&D activities from public and private sectors, and promising pipeline products are anticipated to fuel the relapsed and refractory multiple myeloma treatment market over the forecast years. Moreover, increase in awareness about relapsed and refractory myeloma treatment, government initiations for prevention of cancer, and launching of newer products into the market are bolster the relapsed and refractory multiple myeloma treatment market. However, stringent regulatory policies for product approval, high cost of R&D activities, and adverse effects associated with chemotherapy and radiotherapy may hinder the growth of the market over the forecast timeframe.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 19.8 billion |
Market CAGR |
4.4% |
By Treatment Type |
|
By Drug Class |
|
By Route of Administration |
|
By Distribution Channel |
|
Download Free Sample Report
The global relapsed and refractory multiple myeloma treatment market size was valued at US$ 19.8 billion in 2023 and is poised to grow at a CAGR of 4.4% from 2024-2030.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
relapsed and refractory multiple myeloma treatment market key players are glaxosmithkline plc (u.k.), astrazeneca plc (u.k.),novartis ag (switzerland),teva pharmaceutical industries ltd. (israel)
1.Executive Summary |
2.Global Relapsed And Refractory Multiple Myeloma Treatment Market Introduction |
2.1.Global Relapsed And Refractory Multiple Myeloma Treatment Market - Taxonomy |
2.2.Global Relapsed And Refractory Multiple Myeloma Treatment Market - Definitions |
2.2.1.Treatment Type |
2.2.2.Drug Class |
2.2.3.Route of Administration |
2.2.4.Distribution Channel |
2.2.5.Region |
3.Global Relapsed And Refractory Multiple Myeloma Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Relapsed And Refractory Multiple Myeloma Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Relapsed And Refractory Multiple Myeloma Treatment Market By Treatment Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Chemotherapy, |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Radiotherapy, |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Stem Cell Transplantation, |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Others |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Others |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6.Global Relapsed And Refractory Multiple Myeloma Treatment Market By Drug Class , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Monoclonal Antibodies, |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Immunomodulatory Drugs, |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Proteasome Inhibitors, |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Steroids, |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Others |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
7.Global Relapsed And Refractory Multiple Myeloma Treatment Market By Route of Administration , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Oral, |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Parentera |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Relapsed And Refractory Multiple Myeloma Treatment Market By Distribution Channel , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Hospitals, |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Hospital Pharmacies, |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Retail Pharmacies, |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Online Pharmacies |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
9.Global Relapsed And Refractory Multiple Myeloma Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10.North America Relapsed And Refractory Multiple Myeloma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Chemotherapy, |
10.1.2.Radiotherapy, |
10.1.3.Stem Cell Transplantation, |
10.1.4.Others |
10.1.5.Others |
10.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Monoclonal Antibodies, |
10.2.2.Immunomodulatory Drugs, |
10.2.3.Proteasome Inhibitors, |
10.2.4.Steroids, |
10.2.5.Others |
10.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Oral, |
10.3.2.Parentera |
10.3.3.Others |
10.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Hospitals, |
10.4.2.Hospital Pharmacies, |
10.4.3.Retail Pharmacies, |
10.4.4.Online Pharmacies |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11.Europe Relapsed And Refractory Multiple Myeloma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Chemotherapy, |
11.1.2.Radiotherapy, |
11.1.3.Stem Cell Transplantation, |
11.1.4.Others |
11.1.5.Others |
11.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Monoclonal Antibodies, |
11.2.2.Immunomodulatory Drugs, |
11.2.3.Proteasome Inhibitors, |
11.2.4.Steroids, |
11.2.5.Others |
11.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Oral, |
11.3.2.Parentera |
11.3.3.Others |
11.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Hospitals, |
11.4.2.Hospital Pharmacies, |
11.4.3.Retail Pharmacies, |
11.4.4.Online Pharmacies |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
12.Asia Pacific (APAC) Relapsed And Refractory Multiple Myeloma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Chemotherapy, |
12.1.2.Radiotherapy, |
12.1.3.Stem Cell Transplantation, |
12.1.4.Others |
12.1.5.Others |
12.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Monoclonal Antibodies, |
12.2.2.Immunomodulatory Drugs, |
12.2.3.Proteasome Inhibitors, |
12.2.4.Steroids, |
12.2.5.Others |
12.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Oral, |
12.3.2.Parentera |
12.3.3.Others |
12.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Hospitals, |
12.4.2.Hospital Pharmacies, |
12.4.3.Retail Pharmacies, |
12.4.4.Online Pharmacies |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13.Middle East and Africa (MEA) Relapsed And Refractory Multiple Myeloma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Chemotherapy, |
13.1.2.Radiotherapy, |
13.1.3.Stem Cell Transplantation, |
13.1.4.Others |
13.1.5.Others |
13.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Monoclonal Antibodies, |
13.2.2.Immunomodulatory Drugs, |
13.2.3.Proteasome Inhibitors, |
13.2.4.Steroids, |
13.2.5.Others |
13.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Oral, |
13.3.2.Parentera |
13.3.3.Others |
13.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Hospitals, |
13.4.2.Hospital Pharmacies, |
13.4.3.Retail Pharmacies, |
13.4.4.Online Pharmacies |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Relapsed And Refractory Multiple Myeloma Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
14.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Chemotherapy, |
14.1.2.Radiotherapy, |
14.1.3.Stem Cell Transplantation, |
14.1.4.Others |
14.1.5.Others |
14.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Monoclonal Antibodies, |
14.2.2.Immunomodulatory Drugs, |
14.2.3.Proteasome Inhibitors, |
14.2.4.Steroids, |
14.2.5.Others |
14.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Oral, |
14.3.2.Parentera |
14.3.3.Others |
14.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Hospitals, |
14.4.2.Hospital Pharmacies, |
14.4.3.Retail Pharmacies, |
14.4.4.Online Pharmacies |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.GlaxoSmithKline plc (U.K.) |
15.2.2.AstraZeneca plc (U.K.) |
15.2.3.Novartis AG (Switzerland) |
15.2.4.Teva Pharmaceutical Industries Ltd. (Israel) |
15.2.5.GenMab A/S (Denmark) |
15.2.6.Amgen Inc. (U.S.) |
15.2.7.Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services, Inc.) (U.S.) |
15.2.8.Unum Therapeutics (U.S.) |
15.2.9.Bristol-Myers Squibb (U.S.) |
15.2.10.Celgene Corporation (U.S.) |
15.2.11.Bluebird Bio, Inc. (U.S.) |
16. Research Methodology |
17. Appendix and Abbreviations |
Key Market Players